Next Article in Journal
A Critical Appraisal of New Developments in Intraocular Lens Modifications and Drug Delivery Systems for the Prevention of Cataract Surgery Complications
Next Article in Special Issue
Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19
Previous Article in Journal
Enhancing the Low Oral Bioavailability of Sulpiride via Fast Orally Disintegrating Tablets: Formulation, Optimization and In Vivo Characterization
Previous Article in Special Issue
FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2
Review

Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules

by 1,†, 1,†, 1 and 1,2,*
1
Healthcare Engineering Innovation Center, Department of Biomedical Engineering, Khalifa University of Science and Technology, Abu Dhabi 127788, UAE
2
Khalifa University’s Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi 127788, UAE
*
Author to whom correspondence should be addressed.
Authors have equal contribution.
Pharmaceuticals 2020, 13(12), 447; https://0-doi-org.brum.beds.ac.uk/10.3390/ph13120447
Received: 5 October 2020 / Revised: 5 November 2020 / Accepted: 12 November 2020 / Published: 8 December 2020
(This article belongs to the Special Issue COVID-19 in Pharmaceuticals)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a virus belonging to the Coronavirus family, is now known to cause Coronavirus Disease (Covid-19) which was first recognized in December 2019. Covid-19 leads to respiratory illnesses ranging from mild infections to pneumonia and lung failure. Strikingly, within a few months of its first report, Covid-19 has spread worldwide at an exceptionally high speed and it has caused enormous human casualties. As yet, there is no specific treatment for Covid-19. Designing inhibitory drugs that can interfere with the viral entry process constitutes one of the main preventative therapies that could combat SARS-CoV-2 infection at an early stage. In this review, we provide a brief introduction of the main features of coronaviruses, discuss the entering mechanism of SARS-CoV-2 into human host cells and review small molecules that inhibit SARS-CoV-2 entry into host cells. Specifically, we focus on small molecules, identified by experimental validation and/or computational prediction, that target the SARS-CoV-2 spike protein, human angiotensin converting enzyme 2 (ACE2) receptor and the different host cell proteases that activate viral fusion. Given the persistent rise in Covid-19 cases to date, efforts should be directed towards validating the therapeutic effectiveness of these identified small molecule inhibitors. View Full-Text
Keywords: Covid-19; SARS-CoV-2; spike protein; angiotensin converting enzyme 2; small molecule; inhibitors Covid-19; SARS-CoV-2; spike protein; angiotensin converting enzyme 2; small molecule; inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Al Adem, K.; Shanti, A.; Stefanini, C.; Lee, S. Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules. Pharmaceuticals 2020, 13, 447. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13120447

AMA Style

Al Adem K, Shanti A, Stefanini C, Lee S. Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules. Pharmaceuticals. 2020; 13(12):447. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13120447

Chicago/Turabian Style

Al Adem, Kenana, Aya Shanti, Cesare Stefanini, and Sungmun Lee. 2020. "Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules" Pharmaceuticals 13, no. 12: 447. https://0-doi-org.brum.beds.ac.uk/10.3390/ph13120447

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop